Schrodinger, Inc.

Thank you for standing by. Welcome to Schrodinger's conference call to review fourth quarter and full year 2023 financial results. My name is Mandeep and I'll be your operator for today's call. There will be a question and answer session following management's prepared remarks. At this time, you can ask a question by pressing star one on your telephone keypad. Please be advised that this call is being recorded at the company's request. Now I'd like to welcome your host for today's conference, Mr. Matthew Lucchini, Director of Investor Relations and Corporate Affairs. Please go ahead.

Thank you, and good afternoon, everyone.

Welcome to today's call, during which we will provide an update on the company and review our fourth quarter and full year 2023 financial results. Earlier today, we issued a press release summarizing our financial results and progress across the company, which is available on our website at schrodinger.com. Here with me on our call today are Rami Fareed, Chief Executive Officer, Jeff Porges, Chief Financial Officer, and Karen Akinsanyan, President of R&D Therapeutics. Following our prepared remarks, we'll open the call for Q&A. During today's call, management will make statements that are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to our outlook for the full year 2024, our plans to accelerate the growth of our software business and advance our collaborative and proprietary drug discovery programs, the timing of, initiation of, and readout from our clinical trials, the clinical potential and properties of our compounds, the use of our cash resources, as well as our future expenses. These forward looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects. which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially due to a number of important factors, including the considerations described in the risk factors section and elsewhere in the filings we make with the SEC, including our Form 10-K for the year ended December 31, 2023. These forward-looking statements represent our views only as of today, and we caution you that, except as required by law, we may not update them in the future. whether as a result of new information, future events, or otherwise. Also included in today's call are certain non-GAAP financial measures. These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and should be considered only in addition to and not a substitute for or superior to GAAP measures. Please refer to the tables at the end of our press release, which is available on our website for reconciliations of these non-GAAP measures to the most directly comparable GAAP measures. With that, I'd like to turn the call over to Rami.